Company intelligence / Profile preview

New River Pharmaceuticals

Radford, Virginia, United Statesnrp-inc.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

New River Pharmaceuticals developed Vyvanse (lisdexamfetamine dimesylate), a next-generation stimulant for ADHD. The company was acquired by Shire plc in April 2007 for $2.6 billion to gain full control of Vyvanse as it entered commercial launch. Clinical results supported its efficacy and differentiated safety profile compared to existing stimulants like Adderall XR[1][4][5].

Therapeutic areas: Psychiatry
Modalities: Small molecules (notably prodrugs; e.g., lisdexamfetamine dimesylate)
Industry: Biotech

Partnerships

Shire plc had been a development and commercialization partner prior to full acquisition; no other major partnerships reported.

Beyond the preview

Go deeper on New River Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New River Pharmaceuticals.